# US 2016/0235829 A1 · Vectors for expression of prostate-associated antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235829 A1
- Document ID: US20160235829A1
- Status: Published application
- Kind: A1
- Application number: 15/146,578
- Filed: 2016-05-04
- Published: 2016-08-18
- Earliest claimed: 2013-11-01
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Joseph John BINDER
- Web page: https://patentgrep.com/patent/US20160235829A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/001193: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR}
- A61K 39/001194: {Prostate specific antigen [PSA]}
- A61K 39/001195: {Prostate specific membrane antigen [PSMA]}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/645: {Dendrimers; Multiple antigen peptides}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2317/75: Agonist effect on antigen
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10371: Demonstrated in vivo effect
- C12N 2830/006: tet repressible
- C12N 2840/20: translation of more than one cistron
- C12N 2840/203: having an IRES
- C12Y 304/21077: Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A C68 vector comprising:
(1) a C68 nucleotide sequence; and
(2) a multi-antigen construct comprising at least two coding nucleotide sequences, wherein each of the two coding nucleotide sequences encodes an immunogenic PAA polypeptide selected from the group consisting of:
(i) an immunogenic PSA polypeptide;
(ii) an immunogenic PSCA polypeptide; and
(iii) an immunogenic PSMA polypeptide.

### Claim 26 (depends on 25)

The C68 vector according to claim 25, wherein the at least two coding nucleotide sequences encode two different immunogenic PAA polypeptides selected from the group consisting of:
(1) an immunogenic PSMA polypeptide and an immunogenic PSA polypeptide;
(2) an immunogenic PSMA polypeptide and an immunogenic PSCA polypeptide; and
(3) an immunogenic PSA polypeptide and an immunogenic PSCA polypeptide.

### Claim 27 (depends on 26)

The C68 vector according to claim 26, wherein the C68 nucleotide sequence is the sequence of SEQ ID NO: 57 lacking at least one gene selected from the group consisting of E1A, E1B, E2A, E2B, E3, E4, L1, L2, L3, L4 and L5 genes.

### Claim 28 (depends on 27)

The C68 vector according to claim 27, wherein the immunogenic PSA polypeptide comprises an amino acid sequence selected from the group consisting of:
(1) an amino acid sequence comprising amino acids 27-263 of SEQ ID NO:15,
(2) an amino acid sequence comprising amino acids 4-240 of SEQ ID NO:17; and
(3) the amino acid sequence of SEQ ID NO:17.

### Claim 29 (depends on 28)

The C68 vector according to claim 28, wherein the immunogenic PSCA polypeptide comprises an amino acid sequence selected from the group consisting of:
(1) the amino acid sequence of SEQ ID NO:21;
(2) an amino acid sequence comprising amino acids 2-125 of SEQ ID NO:21; and
(3) an amino acid sequence comprising amino acids 4-125 Of SEQ ID NO:21.

### Claim 30 (depends on 29)

The C68 vector according to claim 29, wherein the immunogenic PSMA polypeptide comprises an amino acid sequence selected from the group consisting of:
(1) an amino acid sequence comprising amino acids 15-750 of SEQ ID NO:1;
(2) the amino acid sequence of SEQ ID NO:3;
(3) the amino acid sequence of SEQ ID NO:5;
(4) the amino acid sequence of SEQ ID NO:7;
(5) an amino acid sequence comprising amino acids 4-739 of SEQ ID NO:9;
(6) an amino acid sequence comprising amino acids 4-739 of SEQ ID NO:3;
(7) an amino acid sequence comprising amino acids 4-739 of SEQ ID NO:5;
(8) an amino acid sequence comprising amino acids 4-739 of SEQ ID NO:7; and
(9) the amino acid sequence of SEQ ID NO:9.

### Claim 31 (depends on 30)

The C68 vector according to claim 30, wherein the C68 nucleotide sequence is the sequence of SEQ ID NO: 57 lacking the genes of E1A, E1B, and E3.

### Claim 32 (depends on 31)

The C68 vector according to claim 31, wherein the multi-antigen construct further comprises a separator sequence between the two coding nucleotide sequences.

### Claim 33 (depends on 32)

The C68 vector according to claim 32, wherein the separator sequence is selected from the group consisting of:
(1) a nucleotide sequence encoding a 2A peptide sequence; and
(2) an internal ribosomal entry site (IRES) sequence.

### Claim 34 (depends on 33)

The C68 vector according to claim 33, wherein the 2A peptide sequence is selected from the group consisting of the 2A-peptide sequence of FMDV, ERAV, PTV1, EMC-B, EMCV, TME-GD7, ERBV, TaV, DrosC, CrPV, ABPV, IFV, Porcine rotavirus, human rotavirus, T brucei TSR1, and T cruzi AP endonuclease.

### Claim 35 (depends on 34)

The C68 vector according to claim 34, wherein the 2A peptide sequence is selected from the group consisting of a FMDV 2A-peptide sequence and a TAV 2A peptide sequence.

### Claim 36 (depends on 33)

The C68 vector according to claim 33, wherein the IRES sequence is an EMCV IRES sequence.

### Claim 37 (depends on 27)

The C68 vector according to claim 27, wherein the nucleotide sequence encoding the immunogenic PSA polypeptide is selected from the group consisting of:
(1) the nucleotide sequence of SEQ ID NO:18;
(2) the nucleotide sequence of SEQ ID NO:20;
(3) a nucleotide sequence comprising nucleotides 10-720 of SEQ ID NO:18; and
(4) a degenerate variant of any of the nucleotide sequences provided in (1)-(3).

### Claim 38 (depends on 37)

The C68 vector according to claim 37, wherein the nucleotide sequence encoding the immunogenic PSCA polypeptide is selected from the group consisting of:
(1) the nucleotide sequence of SEQ ID NO:22;
(2) a nucleotide sequence comprising nucleotides 10-372 of SEQ ID NO:22;
(3) a degenerate variant of the nucleotide sequence of SEQ ID NO:22; and
(4) a degenerate variant of the nucleotide sequence comprising nucleotides 10-372 of SEQ ID NO:22.

### Claim 39 (depends on 38)

The C68 vector according to claim 38, wherein the nucleotide sequence encoding the immunogenic PSMA polypeptide is selected from the group consisting of:
(1) the nucleotide sequence of SEQ ID NO:4;
(2) the nucleotide sequence of SEQ ID NO:6;
(3) the nucleotide sequence of SEQ ID NO:8;
(4) the nucleotide sequence of SEQ ID NO:10;
(5) a nucleotide sequence comprising nucleotides 43-2250 of SEQ ID NO:2;
(6) a nucleotide sequence comprising nucleotides 10-2217 of SEQ ID NO:4;
(7) a nucleotide sequence comprising nucleotides 10-2217 of SEQ ID NO:6;
(8) a nucleotide sequence comprising nucleotides 10-2217 of SEQ ID NO:8;
(9) a nucleotide sequence comprising nucleotides 10-2217 of SEQ ID NO:10,
(10) a nucleotide sequence comprising nucleotides 2333-4543 of SEQ ID NO:58;
(11) a nucleotide sequence comprising nucleotides 2324-4543 of SEQ ID NO:58; and
(12) a degenerate variant of any of the nucleotide sequences provided in (1)-(11).

### Claim 40 (depends on 25)

The C68 vector according to claim 25, wherein the multi-antigen construct comprises the nucleotide sequence of SEQ ID NO:28 or a degenerate variant thereof.

### Claim 41 (depends on 25)

A pharmaceutical composition, comprising the vector according to claim 25 and a pharmaceutically acceptable excipient.

### Claim 42 (depends on 41)

A method of treating prostate cancer in a human, comprising administering to the human an effective amount of the pharmaceutical composition according to claim 41.

### Claim 43 (depends on 42)

The method according to claim 42, further comprising administering to the human an effective amount of an immune modulator.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the immune modulator is selected from the group consisting of a CTLA-4 inhibitor, a CD40 agonist, a TLR agonist, a 4-1 BB agonist, a OX40 agonist, a GITR agonist, a PD-1 antagonist, and a PD-L1 antagonist.
